Kaleido Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLDO research report →
Price Chart
About the company
Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19.
- CEO
- Mark A. Wingertzahn
- IPO
- 2019
- Employees
- 76
- HQ
- Lexington, MA, US
Get TickerSpark's AI analysis on KLDO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.26K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.20
- Div Yield
- 0.00%
- Gross Margin
- -113.59%
- Op Margin
- -7940.85%
- Net Margin
- -8178.26%
- ROE
- -580.57%
- ROIC
- -239.53%
Latest fiscal year · YoY change
- Revenue
- $1.10M+13.2%
- Gross Profit
- $-1,254,000+97.7%
- Op Income
- $-87,667,000
- Net Income
- $-90,288,000-10.6%
- EPS
- $-2.16+11.5%
- OCF Growth
- -25.3%
- FCF Growth
- -19.3%
- 52W High
- $0.20
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -1.17
- RSI (14)
- 52
- Avg Volume
- 1.32K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kaleido shifted its 2020 focus to KB109 in COVID-19, while pushing out other programs and extending cash runway into Q1 2021.· May 14, 2020
- Kaleido is starting two outpatient COVID-19 studies of KB109, including a multi-center trial of about 350 patients and a smaller ~50-patient study with microbiome analyses.
- Top-line results for the KB109 multi-center study are expected in Q4 of this year; the company said the program could inform other respiratory infections and broader inflammatory disease work.
- The KB109 study is designed as Supportive Self-Care plus KB109 versus Supportive Self-Care alone, with two weeks of treatment and three weeks of follow-up.
- KB295 in mild-to-moderate ulcerative colitis is planned for ~30 patients, with topline data expected in mid-2021.
- COVID-19 disruptions pushed KB195 UCD data to the second half of 2021, and the KB174 hepatic encephalopathy study is now contingent on partnering and site conditions.
Kaleido said it ended the first quarter with $53.8 million cash on hand and extended its cash runway further into the first quarter of 2021. No revenue, EPS, or gross margin figures were provided on this call. For guidance, the company expects initial topline results for the KB109 COVID-19 multi-center study in Q4, KB295 ulcerative colitis data in mid-2021, and KB195 phase 2 UCD data in the second half of 2021. Management also said the UCD program is facing approximately a six months or more enrollment delay due to COVID-19.
Alison Lawton framed the quarter around adapting the pipeline to the pandemic, emphasizing that Kaleido’s platform gives it flexibility to move quickly into high-unmet-need settings. Her tone was optimistic but cautious: she repeatedly pointed to safety, remote monitoring, and operational adjustments while noting that the first quarter brought unexpected and unprecedented challenges. She also highlighted that the company remains focused on delivering multiple data readouts over the next 18 months.
Will Duke was not the primary speaker in the prepared remarks that were provided, so detailed CFO commentary was limited in the transcript. The key financial update came from management’s statement that cash at quarter-end was $53.8 million and that disciplined operating expense management extended runway into Q1 2021. Management also said KB109 manufacturing should scale like a small molecule, suggesting costs should be in line with typical pharmaceutical costs.
Analysts focused on whether KB109 could support approval, what kind of efficacy signal would be enough to advance, and the total cost and manufacturability of the program. Management said it plans a Pre-IND meeting with the FDA and is prepared for multiple paths depending on the data, including expanding the current study, moving toward a Phase 3, or potentially pursuing an Emergency Use Authorization if there is a meaningful signal. Questions on KB195 centered on COVID-related enrollment delays and the protocol amendment; management said the age range expansion was always planned, enrollment is delayed by roughly six months or more, and endpoint quality has not been harmed. On KB174, management said partnership interest followed positive prior data in cirrhosis patients and that waiting on a partner made sense because of COVID-related site risk.
The positive case from this call is that Kaleido has multiple near-term catalysts, led by Q4 topline data from KB109 in COVID-19. Management sounded confident that the platform can be advanced quickly because the products are orally administered synthetic glycans with scalable manufacturing and limited systemic exposure. The company also pointed to flexibility in study design, remote monitoring, and existing partner interest in KB174 as signs it can keep the pipeline moving despite the pandemic.
The main risks are execution and timing: COVID-19 has already pushed KB195 data into the second half of 2021 and could complicate enrollment across trials. KB174 is effectively on hold until the company secures a partner and site conditions improve, and the company did not offer a clear threshold for success in KB109 beyond directional improvement. With no revenue disclosed and $53.8 million of cash, the company remains dependent on clinical data and financing discipline to reach the next milestones.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 42.62M
- Float Shares
- 42.45M
of shares held by institutions
1 13F filers
Buy/sell ratio 4.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Parametric Portfolio Associates LLC | 105.45K | ▲ 38.82K |
| Amalgamated Financial Corp. | 3.27K | ▲ 3.27K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 28, 22 | van Hylckama Vlieg Johan | other | 2,087 |
| Feb 28, 22 | Korn Jerald | other | 2,046 |
| Jan 14, 22 | van Hylckama Vlieg Johan | other | 350,000 |
| Jan 14, 22 | Long Alison S | other | 125,000 |
| Jan 14, 22 | Long Alison S | other | 46,800 |
| Jan 14, 22 | Korn Jerald | other | 250,000 |
| Jan 14, 22 | Korn Jerald | other | 45,240 |
| Jan 14, 22 | Duke William E. | other | 125,000 |
| Jan 14, 22 | Duke William E. | other | 44,990 |
| Jan 14, 22 | Menichella Daniel L | other | 250,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KLDO coverage
Recent articles, reports, and earnings notes.
No research on KLDO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KLDO report →Contrasting Kaleido Biosciences (NASDAQ:KLDO) and Adial Pharmaceuticals (NASDAQ:ADIL)
defenseworld.net · Feb 18
Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR
pennystocks.com · Apr 14
Dear KLDO Stock Fans, Mark Your Calendars for April 28
investorplace.com · Apr 13
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes
pennystocks.com · Apr 13
Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why
benzinga.com · Apr 8
ORIC Stock Plunges on Discontinuation of Oncology Candidate
zacks.com · Mar 23
Here's Why Kaleido Biosciences, Inc. (KLDO) is Poised for a Turnaround After Losing 33.2% in 4 Weeks
zacks.com · Feb 4
Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress
globenewswire.com · Jan 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.